Impact of new diagnostic methods on the differential diagnosis and treatment of secondary amenorrhoea.
The development of homologous prolactin assays, multiple pituitary stimulation, tomography, and computerised axial tomography permit more detailed investigation of patients with secondary amenorrhoea than was formerly possible. 39% of 90 patients with secondary amenorrhoea had hyperprolactinaemia. 10 patients (11% of total) had pituitary tumours. 8 of these women had galactorrhoea (27% of those with galactorrhoea). For patients with hyperprolactinaemia but no tumour, bromocriptine is the treatment of first choice rather than clomiphene or human gonadotrophins. The best treatment for patients with detectable tumour is controversial, particularly when the tumour is confined to the sella turcica. Whether or not these tumors are true neoplasms remains to be determined. Clinically, a history of secondary anemorrhoea with or without galactorrhoea following withdrawal of oral contraceptives remains the commonest presenting syndrome.
D000568:Amenorrhea / Q000139:chemically induced / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D001971:Bromocriptine / Q000627:therapeutic use*; D003276:Contraceptives, Oral / Q000009:adverse effects; D003937:Diagnosis, Differential; D004873:Ergolines / Q000627:therapeutic use*; D005260:Female; D005687:Galactorrhea / Q000150:complications*; D006801:Humans; D007775:Lactation Disorders / Q000150:complications*; D010901:Pituitary Function Tests; D010911:Pituitary Neoplasms / Q000150:complications*; D011011:Pneumoencephalography; D011247:Pregnancy; D011388:Prolactin / Q000097:blood; D014054:Tomography; D014057:Tomography, X-Ray Computed
D003276:Contraceptives, Oral; D004873:Ergolines; D001971:Bromocriptine; D011388:Prolactin